Introduction {#Sec1}
============

Mineral nanoparticles (NPs) have been shown to form in human biological fluids when the concentration of calcium, carbonate and phosphate ions exceeds saturation^[@CR1]--[@CR19]^. These mineral particles represent the first mineral that forms in bones and teeth, as well as in ectopic calcifications and kidney stones^[@CR13]^. The particles have been detected in the body fluids and tissues of patients suffering from various conditions, including atherosclerosis, chronic kidney disease and type 2 diabetes^[@CR5],[@CR13]^. As such, the particles represent precursors of physiological and pathological mineralization processes that occur in the human body.

Recent studies indicate that the mineral particles participate in other physiological roles *in vivo*. For instance, the particles form in the lumen of human intestines where they bind to dietary antigens and bacteria-derived molecules such as peptidoglycan; the particles in turn present these molecules to macrophages and dendritic cells of the intestinal mucosa to induce immunological tolerance against food and the gut microbiota^[@CR20]^. Similar mineral particles called calciprotein particles (CPPs) have also been detected in ruptured fetal membranes from idiopathic preterm birth, suggesting that the particles may also affect human fertility and fetal development^[@CR21]^.

We suggested earlier that mineral particles forming in the human body may influence physiological processes by binding to various organic molecules in biological fluids^[@CR13]^. Accordingly, proteins bind to the particles and form a "protein corona"^[@CR7]^, possibly influencing the levels of these proteins in biological fluids. Identification of the molecules that bind to the mineral particles is needed to assess the effects of the particles' organic components *in vivo*. Based on various techniques including biological staining, fluorescent tagging, electrophoresis, chromatography, proteomics and metabolomics, we present here a comprehensive analysis of the organic corona of mineral particles formed in bovine and human serum.

Methods {#Sec2}
=======

Preparation of particles {#Sec3}
------------------------

The use of human body fluids was approved by the Institutional Review Board of Linkou Chang Gung Memorial Hospital. Written informed consent was obtained from the healthy volunteers who provided the samples. The experiments were performed in accordance with the relevant guidelines and regulations. Human blood was withdrawn and serum was prepared as described before^[@CR2]^. Particles were prepared by adding 3 mM of CaCl~2~ and Na~2~HPO~4~ each to Dulbecco's modified Eagle's medium (DMEM; Gibco; final volume of 1 ml) containing or not 10% (v/v) fetal bovine serum (FBS; Biological Industries) or human serum (HS). Following incubation in cell culture conditions overnight, the particles were centrifuged at 16,000 × g for 10 min and washed with 20 mM HEPES buffer containing 1 mM CaCl~2~, 2 mM Na~2~HPO~4~, 150 mM NaCl (pH 7.4). Particles were resuspended in 0.5 ml of double-distilled water or 50 μl of 0.5 mM EDTA.

Electron microscopy and spectroscopy analyses {#Sec4}
---------------------------------------------

Electron microscopy and spectroscopy analyses were performed as before^[@CR2]^. Briefly, washed samples were deposited on Formvar carbon-coated grids and excess water was removed. Dried samples were observed under a field-emission S-5000 scanning electron microscope (Hitachi). Energy-dispersive X-ray spectroscopy (EDX) was performed using an EMAX Energy EX-400 EDX device and the software provided by the manufacturer (Horiba). For Fourier-transform infrared (FTIR) spectroscopy, dried samples were mixed 1:100 (w/w) with KBr and analyzed using a Nicolet 5700 FTIR spectrometer (Thermo Fisher Scientific). For Raman spectroscopy, dried samples were examined using the inVia Raman confocal microscope (Renishaw) equiped with a 50 × objective and a charge-coupled device detector. For X-ray diffraction analysis, dried samples were studied using the D5005 X-ray diffractometer (Bruker) and the obtained spectra were compared with the Joint Committee on Powder Diffraction and Standards.

Coomassie blue staining {#Sec5}
-----------------------

Particles (50 μl) were mixed with 50 μl of Coomassie blue staining solution (0.1% w/v Coomassie Brilliant Blue R-250, Sigma; 50% v/v methanol and 10% v/v glacial acetic acid), followed by gentle mixing using the Intelli-Mixer RM2 (Elmi) for 30 min at room temperature. The solution was centrifuged at 16,000 × g for 10 min, and the pellet was resuspended in 500 μl of destaining solution (50% v/v methanol, 10% v/v acetic acid). The solution was mixed for 30 min as above. Destained particles were collected by centrifugation and washed three times with water. Particles were resuspended in 20 μl of water, and 10 μl of the solution was deposited onto a glass slide, covered with a cover slip, and observed under a BX-51 optical microscope (Olympus).

Oil red O staining {#Sec6}
------------------

A stock solution of oil red O stain was prepared by dissolving 0.5 g of oil red O dye (Merck Millipore) in 100 ml of isopropanol in a warm water bath. The staining solution was prepared by mixing 30 ml of the stock solution with 20 ml of water. The solution was allowed to stand at room temperature for 10 min, prior to filtration into a Coplin jar. The oil red O staining solution (50 μl) was mixed with particles (50 μl) and incubated for 30 min at room temperature. After staining, particles were collected by centrifugation and washed three times with water. Particles were resuspended in 20 μl of double-distilled water and observed using optical microscopy.

Alcian blue staining {#Sec7}
--------------------

The staining solution was prepared by dissolving 1 g of alcian blue 8GX (A5268, Sigma) in 100 ml of 3% (v/v) glacial acetic acid. The pH was adjusted to 2.5 and the solution was filtered into a Coplin jar. The alcian blue staining solution (50 μl) was mixed with 50 μl of particles, and the solution was incubated with gentle agitation for 30 minutes at room temperature. Particles were collected by centrifugation and washed three times with water, prior to observation under optical microscopy.

SYBR gold staining {#Sec8}
------------------

The SYBR gold nucleic acid staining solution (S11494, Invitrogen) was diluted in water (2.5 μl of the 10,000 × SYBR solution into 1 ml of water). An aliquot of the solution (30 μl) was mixed with particles (50 μl) and incubated with gentle agitation for 30 min at room temperature in the dark. After staining, the particles were colleted by centrifugation and washed three times with water. The particles were resuspended in water (20 μl). Microscopic observations were conducted with an epi-fluorescence microscope (AX70, Olympus) using a blue broad-band filter for excitation (488 nm).

Binding assays {#Sec9}
--------------

Bovine serum albumin (BSA; 10 mg; Sigma) was dissolved in 1 ml of water and stored at −20 °C before use. Phosphatidylethanolamine (25 mg; Sigma) was dissolved in 2 ml of chloroform; the solution was dried in a vacuum centrifuge, and 10 ml of water was added, prior to mixing (final concentration of 5 mg/ml). Xanthan gum (0.5 mg; Sigma) was dissolved into 1 ml of water. Salmon sperm DNA (0.3 g; Sigma) was dissolved into 30 ml of water with gentle mixing for 4 hrs at room temperature. Residues were dispersed using a syringe with a 18 G needle. Water was added to obtain a final concentration of 1 mg/ml of DNA.

Particles were also prepared by adding 3 mM of CaCl~2~ and Na~2~HPO~4~ each to DMEM (1 ml, final volume) containing 0.1 to 100 μg of BSA, as well as FBS (10%), phosphatidylethanolamine (25--250 μg), xanthan gum (0.04--20 μg), or salmon sperm DNA (1--30 μg). Following incubation in cell culture conditions for 30 min, the particles were pelleted and washed with 20 mM HEPES buffer (1 ml), prior to resuspension in 50 μl of 50 mM EDTA.

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis {#Sec10}
----------------------------------------------------------

Washed particles were resuspended in EDTA and mixed with 4 × sample denaturing buffer (15 μl), prior to heating at 95 °C for 10 min. Samples (10 μl) were submitted to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein staining was done with Coomassie blue as described earlier^[@CR2]^.

Thin-layer chromatography {#Sec11}
-------------------------

Particles prepared as above using DMEM (1 ml) containing 10% FBS or 25--250 μg of phosphatidylethanolamine were washed and resuspended in EDTA. The solution (20 μl) was loaded onto a 10 cm × 10 cm pre-coated thin-layer chromatography sheet (Alugram Xtra SIL G/UV254, Macherey-Nagel). Lipids were separated in a tank containing a solution of chloroform/methanol/acetic acid/water (50:30:8:2). Staining was performed with iodine vapor.

Dot blotting {#Sec12}
------------

Particles were prepared as above, using DMEM (1 ml) containing 0.04--20 μg of xanthan gum. Particles were treated with EDTA, and the solution (20 μl) was transferred to polyvinylidene difluoride (PVDF) membranes using a dot blot apparatus (Bio-Rad). PVDF membranes were incubated into a blocking solution of phosphate buffered saline (PBS) containing 0.05% (v/v) Tween 20 and 3% (w/v) BSA at room temperature for 2 hrs, and probed with 15 ml of PBS containing 0.2 μg of biotinylated wheat germ agglutinin (WGA; Sigma) at room temperature for 1 hr. After two washing steps using 20 ml of blocking solution containing 1% (w/v) of BSA for 5 min, the PVDF membranes were incubated with 15 ml of blocking buffer containing streptavidin-horseradish peroxidase (HRP) antibody (ab7403, Abcam; 1:25,000) at room temperature with gentle agitation for 30 min. Membranes were washed four times with 20 ml of blocking solution. Signal was revealed with 1 ml of luminol enhancer solution (Promega) based on instructions provided by the manufacturer. Signal was revealed using X-ray radiographic films.

Agarose gel electrophoresis {#Sec13}
---------------------------

Particles were prepared as above, using DMEM (1 ml) containing 1--30 μg of salmon sperm DNA. Particles were treated with EDTA, and the sample (20 μl) was submitted to agarose gel electrophoresis. Gels were stained with ethidium bromide and photographed over a UV trans-illuminator using a digital camera (FluorChem Q System, ProteinSimple).

Proteomic analysis {#Sec14}
------------------

A washed particle specimen corresponding to each condition was resuspended in 50 mM EDTA and treated with a solution of 25 mM NH~4~HCO~3~ containing 10 mM dithiothreitol at 56 °C for 45 min. Samples were treated with 25 mM NH~4~HCO~3~ containing 55 mM iodoacetamide at 22 °C for 30 min. Proteins were digested with 20 μg/ml sequencing-grade porcine trypsin (Promega) at 37 °C overnight. The samples were desalted using a homemade desalting column, prior to drying in a vacuum centrifuge, and resuspension in 0.1% (w/v) formic acid. Samples were loaded into a reverse-phase liquid chromatography trap column (Agilent Technologies, Zorbax 300SB-C18). Peptide separation was performed using a 10-cm analytical C18 column (New Objective, 75 μm internal diameter). Elution was performed by gradually increasing the concentration of acetonitrile (ACN), starting with 2% (v/v) ACN in 0.1% formic acid and ending with 95% ACN. The column was coupled to a LTQ-Orbitrap mass spectrometer operated using the Xcalibur 2.0 software (Thermo Fisher Scientific). Proteomic analysis was performed as described earlier^[@CR7]^.

Metabolomic analysis {#Sec15}
--------------------

Ultra-performance liquid-chromatography (UPLC) was performed using an Acquity BEH C18 column (Waters; 130 Å, 1.7 μm, 2.1 mm × 100 mm). Mass spectrometry was done using time-of-flight (TOF) Synapt HDMS system (Waters). UPLC-grade solvents were purchased from Fluka. Capillary and cone voltage were set at 3000 V (2000 V in ESI^−^ mode) and 35 V, respectively. Desolvation gas flow rate was 700 l/h, and gas flow was maintained at 25 l/h. Desolvation and source temperatures were respectively set at 300 °C and 80 °C. LockSpray frequency was set at 0.5 sec and was averaged over 10 scans for correction. Metabolites were validated by comparing candidate MS spectra with that of metabolite standards (Sigma). Data analysis of a sample corresponding to each condition as well as compound identification were performed as before^[@CR17]^.

Results {#Sec16}
=======

We observed earlier that mineral NPs prepared by mixing calcium and phosphate ions into a cell culture medium (i.e., DMEM) containing a body fluid such as serum are similar to the mineral particles detected in the human body in terms of their size, morphology, structure and composition^[@CR15]^. We therefore used these mineral particles to determine the organic compounds that bind to biological particles in body fluids of animals and humans. We also examined specimens prepared without serum in order to assess the effects of the latter on particle formation. Under scanning electron microscopy (SEM), specimens prepared by adding calcium and phosphate into DMEM in the absence of serum produced mineralized biofilm-like structures in which no distinct particles were discernible (Fig. [1A](#Fig1){ref-type="fig"}, "Serum-Free Sample"). However, in the presence of FBS, the specimens contained round NPs and microparticles with diameters of 50 nm to 1 μm (Fig. [1B](#Fig1){ref-type="fig"}, "FBS-Particles"), consistent with our initial observations that organic compounds such as proteins induce the formation of round and amorphous mineral particles in biological fluids^[@CR2],[@CR3]^.Figure 1Morphology and chemical composition of mineralo-organic particles used in the present study. Specimens were prepared by adding 3 mM of CaCl~2~ and Na~2~HPO~4~ each into DMEM with or without 10% FBS as described in the Methods. Following incubation in cell culture conditions overnight, the specimens were prepared for (**A**,**B**) SEM, (**C**) EDX spectroscopy, (**D**) FTIR spectroscopy, (**E**) Raman spectroscopy, and (**F**) powder X-ray diffraction analysis. The images and spectra shown here and in the other figures are representative results of experiments performed in triplicate.

We used spectroscopy analysis to examine the composition of the particles. Under EDX spectroscopy, the samples prepared in the presence or absence of FBS showed peaks of carbon, calcium, oxygen and phosphorus (Fig. [1C](#Fig1){ref-type="fig"}). A minor peak of sulfur was also noticed in FBS-particles (Fig. [1C](#Fig1){ref-type="fig"}). We used FTIR spectroscopy to determine the chemical functional groups found in the mineral phase of the prepared samples. Serum-free samples and FBS-particles showed peaks corresponding to water and amide bonds (possibly due to the presence of water, DMEM components, and/or serum proteins), in addition to carbonate and phosphate groups (Fig. [1D](#Fig1){ref-type="fig"}). Phosphate peaks were also detected in serum-free samples and FBS-particles using Raman spectroscopy (Fig. [1E](#Fig1){ref-type="fig"}). While no crystalline peaks were observed in the X-ray diffraction pattern of serum-free samples, FBS-particles showed a minor peak corresponding to calcium phosphate (Fig. [1F](#Fig1){ref-type="fig"}).

We used chemical dyes such as Coomassie blue, oil red O, alcian blue and SYBR gold in order to determine the presence of proteins, lipids, polysaccharides, and DNA, respectively, within the particles. While serum-free mineral samples did not stain with any of these dyes (Fig. [2A--E](#Fig2){ref-type="fig"}; minor positive staining was attributed to auto-fluorescence in E), particles prepared in the presence of FBS or HS ("HS-Particles") showed positive staining for all chemical dyes tested (Fig. [2F--O](#Fig2){ref-type="fig"}). These results indicate that the main classes of organic compounds are present within the particles.Figure 2Staining of mineralo-organic particles observed under optical microscopy. Specimens were prepared by adding 3 mM of CaCl~2~ and Na~2~HPO~4~ each into DMEM with or without 10% FBS or HS, followed by washing and staining with dyes that bind to proteins (Coomassie blue), lipids (oil red O), polysaccharides (alcian blue) or DNA (SYBR gold) as described in Methods. Stained specimens were observed under an optical microscope with a bright field condenser (**A**--**D**,**F**--**I**,**K**--**N**) or with an epi-fluorescence microscope (**E**,**J**,**O**). Scale bars: 10 μm.

To confirm the binding of organic compounds to mineral particles, we prepared specimens in cell culture medium containing purified organic compounds. While serum-free specimens did not show any protein staining as assessed by SDS-PAGE, FBS-particles stained for proteins (Fig. [3A](#Fig3){ref-type="fig"}). Similarly, serum-free specimens prepared in the presence of albumin showed dose-dependent protein staining (Fig. [3A](#Fig3){ref-type="fig"}). Serum-free specimens and FBS-particles did not show the presence of the phospholipid phosphatidylethanolamine (PE) as assessed by thin-layer chromatography; however, FBS-particles prepared in the presence of PE showed dose-dependent PE staining (Fig. [3B](#Fig3){ref-type="fig"}). We also prepared mineral samples in the presence of the polysaccharide xanthan gum, and performed dot blots with biotinylated wheat germ agglutinin to determine the binding of the polysaccharide to the particles (Fig. [3C](#Fig3){ref-type="fig"}). While serum-free specimens and FBS-particles showed no detectable staining, FBS-particles prepared in the presence of xanthan gum showed dose-dependent staining for the polysaccharide (Fig. [3C](#Fig3){ref-type="fig"}). Experiments were also performed to verify whether DNA bind to the mineral particles. Agarose gel electrophoresis showed that, as expected, serum-free samples prepared in the absence of DNA were not stained by ethidium bromide; however, FBS-particles and FBS-particles prepared in the presence of DNA showed positive staining (Fig. [3D](#Fig3){ref-type="fig"}). These results indicate that mineralo-organic particles bind to proteins, phospholipids, polysaccharides and DNA.Figure 3Mineral particles bind to various organic molecules. Specimens were prepared by adding 3 mM of CaCl~2~ and Na~2~HPO~4~ each into DMEM (1 ml, final volume) containing (**A**) bovine serum albumin, (**B**) phosphatidylethanolamine, (**C**) xanthan gum, or (**D**) salmon sperm DNA at the amounts indicated. The samples were washed in 20 mM HEPES buffer and resuspended in 50 μl of 50 mM EDTA. Specimens were prepared for (**A**) SDS-PAGE, (**B**) thin-layer chromatography, (**C**) dot blot and (**D**) agarose gel as described in Methods. Vertical white lines in (**C**,**D**) were used to separate blots or gels obtained in identical conditions. The full gels or blots are shown.

In order to determine the organic molecules that bind to the particles in a comprehensive manner, we submitted the particles to proteomics analysis. Following incubation and washing steps, the particles were resuspended in EDTA to release proteins. Various proteins were shown to bind to the mineral particles, including calcification inhibitors (i.e., fetuin-A, albumin), complement proteins (i.e., C3, C4-A), coagulation factors (i.e., factor X, prothrombin), glycoproteins (i.e., histidine-rich glycoprotein, vitronectin), apolipoproteins (i.e., A1, B-100, clusterin), and protease inhibitors (i.e., inter-α-trypsin inhibitor) (Table [1](#Tab1){ref-type="table"}). While the proteins that bind to HS-particles and FBS-particles were similar, HS-particles harbored more proteins than FBS-particles (Table [1](#Tab1){ref-type="table"}), possibly due at least in part to the higher concentration of proteins in HS (60 mg/ml) compared with FBS (32 mg/ml), as noted earlier^[@CR4]^.Table 1Protein composition of serum-derived particles.No.ProteinAccession No.MW (kDa)HS-ParticlesFBS-ParticlesemPAISpectraemPAISpectra1Fetuin-AP1276338.39------1.1103.92Complement C3P01024187.030.1721------3AlbuminP0276869.320.1919.9------4Fetuin-AP0276539.300.3715.5------5VitronectinP0400454.270.1710------6Inter-α-trypsin inhibitor heavy chain H2P19823106.400.178.9------7Apolipoprotein B-100P04114515.280.028.9------8AlbuminP0276969.25------0.358.29ProthrombinP0073469.990.16.6------10Complement C4-AP0C0L4192.660.045.5------11Coagulation factor XP0074354.48------0.34.612Coagulation factor XP0074254.700.24.4------13ClusterinP1090952.460.174.4------14Apolipoprotein A1P0264730.760.094.4------15Histidine-rich glycoproteinP0419659.540.074.4------16C4b-binding protein α chainP0400366.990.064.4------17Serum amyloid A-4 proteinP3554214.740.743.3------18ProthrombinP0073570.46------0.123.619Prothymosin-αP0125212.06------12.720Complement C3Q2UVX4187.14------0.073.621α-1-AntitrypsinP0100946.710.093.3------22AfaminP4365269.020.063.3------23SerotransferrinQ2944377.70------0.111.8Proteins were ranked based on the sum of emPAI and spectral counts ("spectra") for HS-particles and FBS-particles. Accession numbers correspond to UniProt entries. MW, molecular weight; emPAI, exponentially modified protein abundance index.

We also performed a metabolomics analysis in order to identify the low-molecular weight compounds that bind to the mineral particles. Organic compounds released from the particles were resuspended in methanol and analyzed using reversed-phase UPLC-MS analysis. In the ESI^+^ mode, the compounds found to bind to the mineral particles included lyso-phosphatidylcholines (lysoPCs), monoacyl-glycerols (MGs), amides (i.e., lauroyldiethanolamide, stearoyldiethanolamide, niacinamide), carbohydrates (i.e., glucose) and amino acids (i.e., L-leucine, L-phenylalanine) (Table [2](#Tab2){ref-type="table"}). In the ESI^−^ mode, the organic compounds identified included mainly lysoPCs and fatty acids (i.e., stearic acid, palmitic acid, oleic acid, myristic acid, margaric acid, pentadecylic acid, palmitoleic acid, linolenic acid, 9-heptadecenoic acid, arachidic acid, docosahexaenoic acid) (Table [3](#Tab3){ref-type="table"}). While HS-particles and FBS-particles interacted with the same organic compounds, variation in signal intensity was noted between these samples (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Organic compounds bound to serum-derived particles and identified in the ESI^+^ mode.\#CompoundID NumberFormulaRT (min)m/zFBS-ParticlesHS-Particles1LysoPC (16:0)HMDB10382C~24~H~50~NO~7~P2.09496.34023639.318967.72MG (18:0)HMDB11535C~21~H~42~O~4~2.57359.31411389.61624.13MG (16:0)HMDB11564C~19~H~38~O~4~2.41331.28221096.1815.74LysoPC (20:4)HMDB10395C~28~H~50~NO~7~P1.94544.3405733.95835.15LysoPC (18:1)HMDB02815C~26~H~52~NO~7~P2.10522.3574442.41019.36GlucoseHMDB06564C~6~H~11~O~6~Na0.48203.0523312.6645.67LysoPC (22:6)HMDB10404C~30~H~50~NO~7~P1.91568.3402251.92374.48LauroyldiethanolamideHMDB32358C~16~H~33~NO~3~1.84288.2536122.2140.69StearoylethanolamideHMDB13078C~20~H~41~NO~2~2.53328.3184105.9101.210CholineHMDB00097C~5~H~14~NO0.52104.106978.9434.211NiacinamideHMDB01406C~6~H~6~N~2~O0.84123.056454.9139.112L-PhenylalanineHMDB00159C~9~H~11~NO~2~0.85166.086747.7154.713L-LeucineHMDB00687C~6~H~13~NO~2~0.81132.102238.665.2Numbers given within parentheses in the "Compound" column correspond respectively to the number of carbons and double bonds found in the fatty acid molecule. Compounds were ranked based on the ion intensity of FBS-particles. ESI, electrospray ionization; HMDB, Human Metabolome Database; ID, identification; MG, mono-acylglycerol; PC, phosphatidylcholine; RT, retention time.Table 3Organic compounds bound to serum-derived particles and identified in the ESI^−^ mode.\#CompoundID NumberFormulaRTm/zFBS-ParticlesHS-Particles1Stearic acidHMDB00827C~18~H~36~O~2~2.80283.262815500.516917.92Palmitic acidHMDB00220C~16~H~32~O~2~2.50255.231711803.814896.43Oleic acidHMDB00207C~18~H~34~O~2~2.51281.24871593.34197.24Myristic acidHMDB00806C~14~H~28~O~2~2.27227.20031500.3411.65Margaric acidHMDB02259C~17~H~34~O~2~2.66269.24791355.61698.26Pentadecylic acidHMDB00826C~15~H~30~O~2~2.39241.21561127.3711.77Palmitoleic acidHMDB03229C~16~H~30~O~2~2.30253.2159624.6548.18Linolenic acidHMDB00673C~18~H~32~O~2~2.33279.2325331.46627.599-Heptadecenoic acidHMDB31046C~17~H~32~O~2~2.40267.2325207.1155.710Arachidic acidHMDB02212C~20~H~40~O~2~3.31311.2954206.8179.611LysoPC (15:0)HMDB10381C~23~H~48~NO~7~P2.07480.3085199.1839.412LysoPC (18:2)HMDB10386C~21~H~48~N~11~O~3~PS1.99564.3322101.51871.313DHAHMDB61088C~22~H~32~O~2~2.21327.232277.21558.5Numbers given within parentheses in the "Compound" column correspond respectively to the number of carbons and double bonds found in the fatty acid molecule. Compounds were ranked based on the ion intensity of FBS-particles. ESI, electrospray ionization; HMDB, Human Metabolome Database; ID, identification; DHA, docosahexaenoic acid; PC, phosphatidylcholine; RT, retention time.

Discussion {#Sec17}
==========

Major advances have been made in the understanding of the protein corona which may influence the effects of NPs in the human body^[@CR22],[@CR23]^. On the other hand, it remained unclear whether other organic molecules may also bind to mineral NPs that form in body fluids. We describe here that the major classes of organic molecules, including proteins, sugars, lipids, polysaccharides and nucleic acids, bind to mineralo-organic particles derived from biological fluids. These organic molecules are likely to stabilize the formation of mineral particles and allow their transport in biological fluids, in a manner similar to what has been described earlier regarding the role of proteins in particle formation^[@CR5],[@CR13]^. While earlier studies have shown that the particles prepared *in vitro* using the approach described in the present study are highly similar to the mineralo-organic particles detected in human tissues^[@CR2]--[@CR4],[@CR15]^, we could not exclude the possibility that minor differences may be observed between the organic molecules that bind to the prepared and isolated particles. Our results suggest that the binding of these organic compounds to particles may influence various physiological and pathological processes occurring *in vivo*, a possibility that remains to be examined in more details.

One of the major findings reported here is that mineralo-organic particles prepared in biological fluids bind to nucleic acids. These mineral-DNA complexes show similarities to virus particles in terms of their sizes and chemical composition. Mineral particles consisting of calcium phosphate are routinelly used for transfection of DNA into eukaryotic cells in culture^[@CR24]^. Calcium phosphate particles have also been used as gene-delivery vectors *in vivo*^[@CR25]^. These observations suggest that cells may internalize mineralo-organic particles in the circulation and in tissues, possibly leading to transfer of DNA between host cells and other organisms, including the gut microbiota. It remains to be seen whether this phenomenon occurs *in vivo* and whether it may produce any effects on the cells and organs in the body.

We propose that the organic compounds found to bind to the mineralo-organic particles may serve as markers to detect and quantify the particles in human tissues and body fluids, as well as to study the formation and role of the biological particles in the human body. Accordingly, proteins such as albumin and fetuin-A have been shown to consistently interact with the mineral particles that form in biological fluids^[@CR2],[@CR4],[@CR7],[@CR13]^. Spectroscopy analyses such as EDX and X-ray diffraction may thus be used in combination with enzyme-linked immunosorbent assay (ELISA), proteomics or metabolomics to detect mineralo-organic particles in biological specimens. Moreover, we expect that the methodology described here will also yield important information regarding the effects of mineralo-organic particles in the body.

Conclusion {#Sec18}
==========

Our results indicate that mineralo-organic particles that form in biological fluids bind to various organic compounds. The major families of organic molecules were all found to bind to the mineral particles, including proteins, lipids, polysaccharides and DNA. The profiling performed in the present study provides a platform to study the effects of such molecule-particle interactions in physiological and pathological processes occurring in the human body.
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